to modern ATMs. I should talk about the front panels—the IBM ATMs won a few
随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
，推荐阅读91视频获取更多信息
“产业振兴是乡村振兴的重中之重”
A session at Authenticate 2025 which explores the nuanced dynamics between passkeys and verifiable digital credentials, and their technological foundations across usability, privacy, trust models, and ecosystems with the goal of answering whether passkeys and verifiable digital credentials are friends or foes—and how these technologies might collaboratively shape the future of secure, user-centric digital identity systems.
$12.99 at ExpressVPN (with money-back guarantee)